NRAS and neoplasm: Among these patients, 324 patients (86%) were evaluable for RAS analysis; 270 (83%) had tumours that were wild-type in exons 2–4 of KRAS and NRAS (i.e., wild-type RAS), and 54 (17%) had a mutation in KRAS exon 3 or 4 or NRAS exons 2, 3, or 4 (Figure 1B and Supplementary Table 1).